

IND SWIFT LABORATORIES INC.

**FINANCIAL STATEMENTS
FOR THE YEAR ENDED
December 31, 2021**



Vishaw Sondhi, CPA, P.C.
Tax, Accounting & Wealth Management Services

Main Office: 100 Broad Street
Eatontown, NJ 07724

Iselin Office: 870 Green Street
Iselin, NJ 08830


January 28, 2022

Accountant's Compilation Report

**To the Stockholder's
Ind Swift Laboratories, Inc.**

We have compiled the accompanying balance sheet of Ind Swift Laboratories, Inc. as of December 31, 2021, and the related statements of income and retained earnings for the period then ended.

The financial statements were compiled in accordance with generally accepted accounting principles. We have not audited or reviewed the accompanying financial statements and accordingly, do not express an opinion on any other form of assurance on them. These financial statements are the responsibility of the company's management.


Vishaw Sondhi, CPA
Certified Public Accountant

IND SWIFT LABORATORIES, INC.

**BALANCE SHEET
AS ON DECEMBER 31, 2021**

ASSETS

	<u>Dec-21</u>
Current Assets:	
Cash in Bank	\$ 139,336
Accounts Receivable	7,624,660
Total Current Assets	<u>7,763,996</u>
Furniture and Equipments	
Furniture & Equipments	60,494
Accumulated Depreciation	(60,494)
Other Assets - Security Deposit	-
Total Assets	<u><u>7,763,996</u></u>

LIABILITIES & STOCKHOLDERS' EQUITY

Current Liabilities:	
Accounts Payable	5,831,194
Advance	455,611
Taxes Payable	13,000
Other Payable	44,622
Total Current Liabilities	<u>6,344,427</u>
Stockholders' Equity	
Common Stock, no par value, 1500 Shares authorized, 1204 shares issued and outstanding	1,204,000
Retained Earning/ (Deficit)	12,179
Net Income	203,390
	<u>1,419,569</u>
Total Partner's Equity	
Total Liabilities & Stockholders' Equity	<u><u>7,763,996</u></u>

IND SWIFT LABORATORIES, INC

STATEMENT OF OPERATIONS

FOR THE QUARTER ENDED Dec 31, 2021

	<u>QTR Ended Dec-21</u>	<u>Jan 2021 to Dec-21</u>
Income		
Gross Sales	\$ 5,112,784	\$ 17,936,882
Other Income	-	1,896
Net Sales	<u>5,112,784</u>	<u>17,938,778</u>
Cost of Sales	4,881,286	16,597,772
FDA Fees	-	57,557
Gross Profit	<u>231,498</u>	<u>1,283,449</u>
Expenses:		
Selling, General and Administrative	283,507	987,059
Profit (Loss) before taxes	<u>(52,009)</u>	<u>296,390</u>
Taxes on Income	-	93,000
Net Income	<u>(52,009)</u>	<u>203,390</u>